Locana Revenue and Competitors
Estimated Revenue & Valuation
- Locana's estimated annual revenue is currently $5.7M per year.
- Locana's estimated revenue per employee is $77,500
- Locana's total funding is $155.6M.
Employee Data
- Locana has 73 Employees.
- Locana grew their employee count by -21% last year.
Locana Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Locana?
We are creating a new class of precision medicines to treat a range of human genetic diseases. Locana's RNA-targeting technology platform allows us to precisely address these mutations on the level of RNA. By targeting RNA, our approach avoids the risk of off-target effects in DNA and is suited to address many diseases linked to dysfunctional processing of RNA. The wide range of potential indications is supported by the modularity of our RNA-targeting gene therapies which are composed of interchangeable components that provide exquisite control of specificity and activity. We are working hard to realize the potential of RNA-targeting gene therapy to treat a range of devastating illnesses. With world leadership in RNA biology and RNA-mediated disease and a top tier Board of Directors and panel of Scientific Advisors, we are poised to develop the next generation of genomic medicines for functional correction of disease.
keywords:N/A
$155.6M
Total Funding
73
Number of Employees
$5.7M
Revenue (est)
-21%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Locana's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Associate Director, Human Resources | Reveal Email/Phone |
2 | Chairman | Reveal Email/Phone |
3 | Director (former CEO) | Reveal Email/Phone |
4 | Chief Scientific Officer | Reveal Email/Phone |
5 | Sr. Development Associate II | Reveal Email/Phone |
6 | Sr. Research Associate | Reveal Email/Phone |
7 | Senior Research Associate I | Reveal Email/Phone |
8 | Associate Scientist | Reveal Email/Phone |
9 | Executive Director, CMC Analytical and Formulation Development | Reveal Email/Phone |
10 | Director, Gene Therapy Process Development | Reveal Email/Phone |
Locana News
Denver (April 27, 2022) Locana, a leading geographic data and technology company, has won a 10-year National Geospatial Data and...
Locana was formerly known as Critigen. The companies will work closely with clients and identify issues, challenges and mission priorities to...
Photo courtesy of Locanabio. Locanabio will pursue gene therapy treatments for severe neurodegenerative and neuromuscular diseases. San Diego-based Locanabio, a private preclinical-stage biotech company, has raised a $100 million Series B financing to support the advancement of its RNA-targetin ...
San Diego-based Locanabio, a biotech startup developing gene therapy to treat neurodegenerative, neuromuscular, and retinal diseases, has raised $100M in a Series B funding, the company said this morning. The funding was led by Vida Ventures, and also included RA Capital Management, Invus, Acuta ...
Locanabio, a San Diego gene therapy company focused on treatments for severe neurodegenerative diseases such as Huntington’s and Lou Gehrig’s disease, has raised $100 million in a second round of venture capital funding. The Torrey Pines Mesa company will use the money for further pre-clinical ...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $16.4M | 73 | 6% | N/A |
#2 | $17.7M | 73 | 55% | N/A |
#3 | $19.1M | 73 | 4% | N/A |
#4 | $17.7M | 73 | 3% | N/A |
#5 | $17.7M | 73 | 59% | N/A |